F-18 LABELING OF MONOCLONAL-ANTIBODIES AND FRAGMENTS WITH PRESERVATION OF IMMUNOREACTIVITY

被引:60
作者
GARG, PK [1 ]
GARG, S [1 ]
ZALUTSKY, MR [1 ]
机构
[1] DUKE UNIV,MED CTR,DEPT RADIOL,DURHAM,NC 27710
关键词
D O I
10.1021/bc00007a008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A new method is reported for labeling proteins with the positron-emitting nuclide F-18. Initially, 4-[F-18]-fluorobenzylamine was prepared in two steps from aqueous [F-18]fluoride in high yield. The F-18 acylation agent was formed by reaction of this product with disuccinimidyl suberate. Overall yields for the 4-[F-18]fluorobenzylamine succinimidyl ester ([F-18]SFBS), decay corrected to the end of cyclotron bombardment, were about 30% in a synthesis time of 60 min. After a 15-min reaction, 30-45% (decay corrected) of the [F-18]SFBS could be coupled to intact antibodies and their F(ab')2 and Fab fragments. Coupling yields were dependent on protein concentration but not reaction time. HPLC purification of [F-18]SFBS was necessary to obtain optimal coupling efficiency and immunoreactivity. The immunoreactivities of F-18-labeled F(ab')2 and Fab fragments of an antimyosin antibody were 89 +/- 5% and 75 +/- 9%, respectively. Biodistribution studies in normal mice demonstrated similar in vivo behavior of F-18-labeled antibody fragments and those labeled with I-125 by using N-succinimidyl 3-[I-125]iodobenzoate. These results indicate that this method may be useful for labeling monoclonal antibodies and other proteins and peptides with F-18.
引用
收藏
页码:44 / 49
页数:6
相关论文
共 29 条
[1]   LABELED ARYL FLUORIDES FROM THE NUCLEOPHILIC DISPLACEMENT OF ACTIVATED NITRO-GROUPS BY F-18-F- [J].
ATTINA, M ;
CACACE, F ;
WOLF, AP .
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1983, 20 (04) :501-514
[2]  
BOURDON MA, 1983, CANCER RES, V43, P2796
[3]   SYNTHESIS OF 1-(PARA-ISOTHIOCYANATOBENZYL) DERIVATIVES OF DTPA AND EDTA - ANTIBODY LABELING AND TUMOR-IMAGING STUDIES [J].
BRECHBIEL, MW ;
GANSOW, OA ;
ATCHER, RW ;
SCHLOM, J ;
ESTEBAN, J ;
SIMPSON, DE ;
COLCHER, D .
INORGANIC CHEMISTRY, 1986, 25 (16) :2772-2781
[4]  
BUCHEGGER F, 1983, J EXP MED, V158, P413, DOI 10.1084/jem.158.2.413
[5]  
CARASQUILLO JA, 1989, ANTIBODIES RADIODIAG, P169
[6]  
CARREL S, 1980, CANCER RES, V40, P2523
[7]  
Colapinto E V, 1988, Br J Neurosurg, V2, P179, DOI 10.3109/02688698808992668
[8]  
COLCHER D, 1983, CANCER RES, V43, P736
[9]  
ESTEBAN JM, 1987, J NUCL MED, V28, P861
[10]  
GARG PK, 1989, APPL RADIAT ISOTOPES, V40, P485